PROTAC Building Blocks
By Alberta Research ChemicalsTargeted protein degradation (TDP) has been an attractive concept in the drug discovery to selectively remove the disease-causing proteins from the system, and remained as academic interest for several decades until the recent discovery of small molecule proteolysis-targeting chimera (PROTAC) protein degraders.
This PROTAC technology has been widely used both in academia and industry in the last 20 years and in 2020, provided the first clinical proof-of-concept.
To read more, please download this free white paper.